Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Molecular Cancer Therapeutics|February 25, 2010
Identification of expression signatures predictive of sensitivity to the Bcl-2 family member inhibitor ABT-263 in small cell lung carcinoma and leukemia/lymphoma cell linesStephen K Tahir, John Wass, Mary K Joseph, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 31, 2016
ABBV-399, a c-Met Antibody-Drug Conjugate that Targets Both MET-Amplified and c-Met-Overexpressing Tumors, Irrespective of MET Pathway DependenceJieyi Wang, Mark G Anderson, Anatol Oleksijew, et al.
Conservation Biology : the Journal of the Society for Conservation Biology|April 30, 2015
The theory behind, and the challenges of, conserving nature's stage in a time of rapid changeJoshua J Lawler, David D Ackerly, Christine M Albano, et al.
Cancer Research|February 7, 2007
Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737Stephen K Tahir, Xiufen Yang, Mark G Anderson, et al.
Molecular Cancer Therapeutics|August 28, 2020
Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody-Drug ConjugateMark G Anderson, Hugh D Falls, Michael J Mitten, et al.
Pharmacology|July 26, 2017
A "Prozone-Like" Effect Influences the Efficacy of the Monoclonal Antibody ABT-700 against the Hepatocyte Growth Factor ReceptorKedar S Vaidya, Anatol Oleksijew, Lora A Tucker, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 10, 2010
Bcl-XL represents a druggable molecular vulnerability during aurora B inhibitor-mediated polyploidizationO Jameel Shah, Xiaoyu Lin, Leiming Li, et al.
Cancer Research|May 3, 2008
ABT-263: a potent and orally bioavailable Bcl-2 family inhibitorChristin Tse, Alexander R Shoemaker, Jessica Adickes, et al.
Anti-Cancer Drugs|October 14, 2005
A highly potent and selective farnesyltransferase inhibitor ABT-100 in preclinical studiesWen-Zhen Gu, Ingrid Joseph, Yi-Chun Wang, et al.
Neuro-Oncology Advances|February 23, 2023
Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastomaBenedito A Carneiro, Kyriakos P Papadopoulos, John H Strickler, et al.
Pageof 4